- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01348438
Transapical Implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System - The Engager European Pivotal Trial
September 14, 2018 updated by: Medtronic Bakken Research Center
The purpose of the study is to evaluate the safety and clinical performance of the Engager Transcatheter Aortic Valve Implantation System in patients with severe aortic valve stenosis who are at high risk for surgical valve replacement.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
125
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium, 1200
- Cliniques Universitaires Saint- Luc
-
-
-
-
-
Bad Nauheim, Germany, 61231
- Kerckhoff-klinik
-
Bad Oeynhausen, Germany, 32545
- Ruhr-Universität Bochum
-
Cologne, Germany, 50937
- Uniklinik Köln Heart Center
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg- Eppendorf
-
Leipzig, Germany, 04289
- Herzzentrum Leipzig GmbH
-
München, Germany, 80636
- Deutsches Herzzentrum München
-
-
-
-
-
Tel-Hashomer, Israel, 52621
- The Chaim Sheba Medical Center
-
-
-
-
-
Zurich, Switzerland, 8091
- University of Zurich - Klinik für Herzchirurgie, UniversitätsSpital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Severe aortic stenosis defined as one or more of the following by Doppler echocardiography: mean gradient > 40 mmHg; max velocity > 4m/s; aortic valve area ≤ 0.8 cm2.
- Symptoms related to aortic valve disease, and NYHA Functional Class II or greater.
- Logistic EuroSCORE predicted risk for mortality of ≥20%, or comorbidity judged by the investigator to pose an absolute or relative contraindication for conventional aortic valve replacement.
- Patient is indicated for aortic valve implantation with a biological prosthesis (tissue valve) in accordance with the 2007 European Society of Cardiology (ESC) Guidelines for management of valvular heart disease.
- Age ≥ 18 years.
- Echocardiographically determined aortic annulus diameter of ≥19 mm and ≤ 26 mm in a long-axis view.
Exclusion Criteria:
- Congenital unicuspid or bicuspid aortic valve.
- Severe eccentricity of calcification, defined as calcium deposits larger than 6mm in diameter.
- Echocardiographic evidence of intracardiac mass, thrombus, or vegetation.
- Left ventricular ejection fraction < 25%, as determined by contrast ventriculography, or echocardiography or radionuclide angiography if contrast ventriculography not available
- Hypertrophic obstructive cardiomyopathy.
- Patients with life expectancy less than 12 months due to an underlying non-cardiac comorbid disease.
- Known hypersensitivity or contraindication that cannot be adequately controlled with pre-medication to any study medication or material, such as contrast medium or Nitinol.
- Sepsis or acute endocarditis.
- Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding diathesis, or coagulopathy.
- Renal insufficiency assessed by creatinine > 2.5 mg/dl and/or end stage renal disease requiring chronic dialysis.
- Active peptic ulcer or GI bleeding within 3 months from the planned index procedure.
- Untreated clinically significant coronary artery disease requiring revascularization.
- Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring inotropic support or mechanical heart assistance.
- Significant aortic disease, including abdominal and thoracic aortic aneurysm, defined as maximal luminal diameter of 5 cm or greater.
- Need for emergency surgery, cardiac or non-cardiac.
- History of myocardial infarction in the last 6 weeks.
- History of TIA or CVA in the last 6 months.
- Therapeutic invasive cardiac procedure, with the exception of aortic balloon valvuloplasty, performed within 30 days of the planned date of valve implantation, or 6 months in the case of drug-eluting stents.
- Pre-existing prosthetic heart valve or prosthetic ring in any position.
- Mitral regurgitation greater than 2+ by angiography or moderate by echocardiography.
- Patient refuses a blood transfusion.
- Patient is currently enrolled in another investigational device or drug trial that may influence the outcome of this trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm study
|
Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All-cause mortality
Time Frame: 30 Days
|
All-cause mortality within 30 days post-implantation
|
30 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) free survival at 30 days and 6 months post implantation
Time Frame: 6 months
|
6 months
|
Device and procedure related Major Adverse Events
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Volkmar Falk, Prof., University of Zurich
- Principal Investigator: Jean-Louis Vanoverschelde, Prof., Cliniques Universitaires Saint-Luc, Brussels
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2011
Primary Completion (Actual)
February 28, 2013
Study Completion (Actual)
January 25, 2018
Study Registration Dates
First Submitted
May 4, 2011
First Submitted That Met QC Criteria
May 4, 2011
First Posted (Estimate)
May 5, 2011
Study Record Updates
Last Update Posted (Actual)
September 18, 2018
Last Update Submitted That Met QC Criteria
September 14, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENG CIP-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Valve Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisGeorgia
-
Ningbo Jenscare Biotechnology Co., Ltd.UnknownAortic Regurgitation | Severe Aortic Stenosis
-
Anteris Technologies Ltd.Active, not recruitingAortic Stenosis | Aortic Valve Calcification | Severe Aortic Valve Stenosis | Symptomatic Aortic StenosisUnited States
-
The Medicines CompanyCompletedTranscatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic StenosisNetherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
-
Edwards LifesciencesActive, not recruitingAortic Stenosis | Aortic Regurgitation | Symptomatic Aortic StenosisChina
-
Edwards LifesciencesCompletedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Sorin Group USA, Inc.TerminatedAortic Valve Stenosis | Aortic Valve Stenosis With Insufficiency | Regurgitation, Aortic Valve | Aortic Valve IncompetenceUnited States
-
Edwards LifesciencesActive, not recruitingHeart Failure | Aortic Stenosis | Mitral Valve Insufficiency | Aortic Valve Insufficiency | Mitral StenosisUnited States, Canada, Poland
-
Genesis Medtech CorporationRecruitingDiseases of Aortic Valve | Aortic Stenosis DiseaseChina
-
BC Centre for Improved Cardiovascular HealthEdwards LifesciencesUnknownTranscatheter Aortic Valve Implantation | Severe Aortic StenosisCanada
Clinical Trials on Medtronic Engager Transcatheter Aortic Valve Implantation System
-
Medtronic Bakken Research CenterCompleted
-
Medtronic CardiovascularActive, not recruitingSevere Aortic StenosisUnited States, Netherlands, Canada, Spain, Denmark, United Kingdom, Switzerland, Germany, Sweden
-
Medtronic CardiovascularActive, not recruiting
-
Medtronic CardiovascularCompleted
-
Medtronic CardiovascularCompleted
-
Sahlgrenska University Hospital, SwedenCompleted
-
Medtronic Bakken Research CenterCompleted
-
Didier TCHETCHEAbbottNot yet recruitingBicuspid Aortic ValveFrance
-
Clinique PasteurUnknownBicuspid Aortic ValveFrance
-
National and Kapodistrian University of AthensUniversity General Hospital of Heraklion; Naval Hospital, Athens; Silesian Centre... and other collaboratorsCompleted